European Commission Approves Risankizumab for Plaque Psoriasis European Commission Approves Risankizumab for Plaque Psoriasis

In clinical studies, patients with moderate to severe plaque psoriasis saw significantly higher rates of skin clearance with risankizumab compared to current standards of care.International Approvals

Source: Medscape Dermatology Headlines - May 1, 2019 Category: Dermatology Tags: Dermatology News Alert Source Type: news